HSANZ Free Communications 2: Myeloma
Tracks
HSANZ
| Monday, October 19, 2026 |
| 8:30 AM - 10:00 AM |
| 515 |
Speaker
Dr Su Li
Associate Chief Physician
Liquan Hospital / Gobroad Medical Institute of Hematology / Shanghai Center
Phase 1 study of SL0349, a bispecific nanobody based BCMA/GPRC5D CAR-T,in relapsed or refractory multiple myeloma
8:30 AM - 8:45 AMBiography
Li Su, M.D., Ph.D., is Associate Chief Physician and Director of Hematology and Myeloma Center at Gobroad Shanghai Liquan Hospital. Formerly at Shanghai First People's Hospital for 10 years, he specializes in CAR-T therapy, acute leukemia, multiple myeloma, lymphoma, transplant management, and pulmonary complications.
Dr Georgia McCaughan
Haematologist
St Vincent's Hospital
Presence of end organ damage at commencement of second line therapy significantly impacts outcomes in Multiple Myeloma: An Australia and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
8:45 AM - 9:00 AMBiography
Georgia McCaughan is a Staff Specialist Haematologist at St Vincent’s Hospital, Sydney with a clinical and research interest in plasma cell dyscrasias.
Dr Daniel Wong
Haematologist
The Alfred Hospital
Circulating plasma MYC/BCL2 RNA co-expression in newly diagnosed multiple myeloma identifies patients with a higher risk of early progression
9:00 AM - 9:15 AMBiography
Dr Daniel Wong is currently a fractional staff at Bayside Health Alfred and a member of Haematology Society of Australia and New Zealand (HSANZ). He is also currently undertaking his PhD in multiple myeloma with Myeloma Research Group, Australian Centre for Blood Diseases (ACBD).
Ms Belinda Maher
Research Assistant
Monash University
Exploiting Glucocorticoid-Induced Leucine Zipper (GILZ) to deliver the anti-myeloma effects of steroids without metabolic toxicities
9:15 AM - 9:30 AMBiography
For the past 10 years, Ms. Belinda Maher has worked as a Research Assistant in the Blood Cancer Therapeutics Laboratory lead by Professor Jake Shortt. During this time she has made research contributions towards a variety of blood cancers with a current focus on myeloma.
Dr Jesse Zhang
Registrar
Health New Zealand
Ethnic disparities in cytogenetic characteristics at diagnosis and survival of multiple myeloma patients within the Auckland region
9:30 AM - 9:45 AMBiography
Jesse is a joint haematology trainee from Auckland, New Zealand. He has completed two years of clinical training and is currently working on his laboratory component.
Prof P Joy Ho
Clinical Professor Haematology
Royal Prince Alfred Hospital
Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma
9:45 AM - 10:00 AMBiography
Prof. Joy Ho is Clinical Professor, University of Sydney and Senior Staff Specialist, Royal Prince Alfred Hospital. President of the Haematology Society of Australia & New Zealand 2013-15. Member of International Myeloma Working group, on the Scientific Advisory Board, International Myeloma Foundation. Currently Principal Investigator, ALLG MM16 myeloma clinical trial.
Assoc / Prof Rodger Tiedemann
Haematologist / Associate Professor
Health New Zealand / University of Auckland
Chairperson
Biography
Dr Rodger Tiedemann (MBChB, PhD, FRACP, FRCPA) is Associate Professor at the Universities of Auckland and Toronto, Morris Fellow in Cancer Research, and a Haematologist at Auckland City Hospital. Recipient of the ASH Scholar Award and Canadian Cancer Society Rawls Prize, he studies multiple myeloma adaptive cell states and resistance to cure, and develops novel bispecific antibody therapies.
Assoc Prof Cindy Lee
Consultant
Royal Adelaide Hospital
Chairperson
Biography
Associate Professor Cindy Lee is a haematologist in Adelaide, co‑leading the myeloma program and clinical trials. She trained in Perth and completed an EBMT fellowship in the UK. She serves on MSAG, IMS, CIBMTR, WBMT and ALLG myeloma committees, contributing internationally to myeloma research and practice.
